Literature DB >> 18985308

[Rheumatoid arthritis today].

N Leuchten1, M Aringer.   

Abstract

Advances in the therapy of rheumatoid arthritis with disease modifying antirheumatic drugs (DMARD) such as methotrexate and biological response modifiers in particular, have turned a chronic progressive disease with significant invalidity and mortality into one that can be well controlled. To prevent irreversible damage, early diagnosis is essential. DMARD therapy needs to be instituted within three months after symptom onset - a clinical and organisational challenge. Long term DMARD therapy is monitored using standardized scores and modified whenever not sufficiently successful. Analgesia, physiotherapy and occupational therapy as well as orthopaedic surgery play important roles in the management of rheumatoid arthritis. Consequent multimodal therapy can decisively influence the course of the disease and prevent or at least minimize damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985308     DOI: 10.1007/s00108-008-2228-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

1.  [Reducing toxicity of methotrexate with folic acid].

Authors:  P Harten
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 3.  The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis.

Authors:  Feng Xie
Journal:  Arthritis Rheum       Date:  2008-07-15

4.  Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

Authors:  William B White; Christine R West; Jeffrey S Borer; Philip B Gorelick; Lisa Lavange; Sharon X Pan; Ethan Weiner; Kenneth M Verburg
Journal:  Am J Cardiol       Date:  2006-11-10       Impact factor: 2.778

Review 5.  Smoking as a trigger for inflammatory rheumatic diseases.

Authors:  Lars Klareskog; Leonid Padyukov; Lars Alfredsson
Journal:  Curr Opin Rheumatol       Date:  2007-01       Impact factor: 5.006

6.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Authors:  E Keystone; P Emery; C G Peterfy; P P Tak; S Cohen; M C Genovese; M Dougados; G R Burmester; M Greenwald; T K Kvien; S Williams; D Hagerty; M W Cravets; T Shaw
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

7.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

Review 8.  [Early rheumatoid arthritis--rapid help is double help].

Authors:  M Aringer; N Leuchten; K P Machold
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

Review 9.  Disease activity measures for rheumatoid arthritis.

Authors:  M Dougados; D Aletaha; P van Riel
Journal:  Clin Exp Rheumatol       Date:  2007 Sep-Oct       Impact factor: 4.473

10.  [RheumaCheck: development and evaluation of a German language screening instrument for rheumatic diseases].

Authors:  Jutta G Richter; Ewa Wessel; Ralf Klimt; Reinhardt Willers; Matthias Schneider
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.